AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33010968
Drug: Multimodal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pelvic floor physical therapy (12 weekly 60‐min sessions)
Trial: 33010968
Drug: Multimodal pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal pelvic floor physical therapy
Trial: 33117131
Drug: 10 Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 Hz rTMS treatment
Trial: 33117131
Drug: No-stim control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-stim control treatment
Trial: 33567218
Drug: Violet light-emitting
RxNorm normalized name: Gentian Violet
DrugBank: Gentian violet cation (DB00406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Violet light-emitting diodes (LEDs) device emitting violet light (405-410 nm) without peroxide-containing bleaching gel
Trial: 35346348
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual + DIALOG scale
Trial: 35702866
Drug: Hypothetical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical therapy improvements in silico
Trial: 33037726
Drug: Nifekalant 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifekalant 0.4 mg/kg
Trial: 33037726
Drug: Nifekalant 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifekalant 0.5 mg/kg
Trial: 33037726
Drug: Nifekalant 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifekalant 0.3 mg/kg
Trial: 36055874
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg FMP013 / 0.5 mL ALFQ (Low dose group)
Trial: 36055874
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg FMP013 / 1.0 mL ALFQ (High dose group)
Trial: 36125053
Drug: Curcumin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin supplementation (2g daily for 6 weeks)
Trial: 35169169
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (200 mL single transfusion)
Trial: 32134882
Drug: PowerPoint-based e-CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PowerPoint-based e-CBT delivered via email (12 weekly modules and homework assignments)
Trial: 35973787
Drug: Optimised standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised standard medical therapy (SMT)
Trial: 32735053
Drug: 16-week smartphone-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-week smartphone-based aftercare intervention with therapist feedback as add-on to treatment as usual (TAU)
Trial: 33258495
Drug: Daily chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chlorhexidine showers and mupirocin nasal ointment twice a day for 5 days before surgery (S. aureus carrier group)
Trial: 33258495
Drug: Daily chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily chlorhexidine showers (noncarrier group)
Trial: 36347059
Drug: Oral combination
RxNorm normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combination regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) for 24 weeks
Trial: 36347059
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment of anal high-grade squamous intraepithelial lesions
Trial: 32696227
Drug: Intravenous 5%
RxNorm normalized name: immune globulin intravenous 5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5% dextrose in 0.9% normal saline (according to weight-based maintenance rate)
Trial: 32696227
Drug: Dexamethasone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.15 mg·kg−1 iv) and ondansetron (0.05 mg·kg−1 iv)
Trial: 35386725
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received the same anesthetic drugs
Trial: 32126977
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg oral daily for 6 months
Trial: 32126977
Drug: IFN-β 1b
RxNorm normalized name: IFN-gamma 1b
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-β 1b 250 μg subcutaneous every other day for 6 months
Trial: 34371162
Drug: ALED program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALED program in combination with Our Voice (neighborhood-level citizen science intervention)
Trial: 32077891
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) starting 2 to 6 weeks after chemoradiotherapy
Trial: 32077891
Drug: Pembrolizumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (100 mg IV every 3 weeks) starting day 29 of chemoradiotherapy
Trial: 32077891
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) starting day 29 of chemoradiotherapy
Trial: 32077891
Drug: Pembrolizumab (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (100 mg IV every 3 weeks) starting day 1 of chemoradiotherapy
Trial: 32077891
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg IV every 3 weeks) starting day 1 of chemoradiotherapy
Trial: 32077891
Drug: Pembrolizumab (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (at least 1 dose)
Trial: 32077891
Drug: Pembrolizumab (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (at least 2 doses)
Trial: 35468266
Drug: Group-based outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based outpatient physical therapy intervention delivered six weeks after TKR.
Trial: 33999707
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg dronabinol
Trial: 35857131
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg kg−1)
Trial: 32816639
Drug: Buspirone (7.5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (7.5-15 mg twice daily)
Trial: 33118401
Drug: Peppermint extract
RxNorm normalized name: peppermint allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint extract (40 drops mixed in 20 cc of tap water every 8 hours)
Trial: 33118401
Drug: Distilled water
RxNorm normalized name: Distilled Water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water (40 drops mixed in 20 cc of tap water every 8 hours)
Trial: 33653385
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention including identification and screening of household contacts, referral of contacts with TB-suggestive symptoms, and household initiation of preventive therapy.
Trial: 36209981
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy with gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) for 2 preoperative and 4 postoperative cycles (arm A)
Trial: 36209981
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with gemcitabine (1000mg/m2) and nab-Paclitaxel (125mg/m2) for 6 cycles (arm B)
Trial: 33813638
Drug: Combined Nd:YAG/Er:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Nd:YAG/Er:YAG laser therapy (test group)
Trial: 33813638
Drug: Turned off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turned off laser therapy (control group)
Trial: 33176043
Drug: Gabapentin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (100 mg daily for 4 weeks)
Trial: 33176043
Drug: Doxepin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (10 mg daily for 4 weeks)
Trial: 36064130
Drug: Autologous platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous platelet-rich gel combined with conventional treatment and TCM
Trial: 36064130
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy and TCM
Trial: 34155984
Drug: Youper app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Youper app (AI therapy)
Trial: 34210720
Drug: Proactive therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proactive therapeutic drug monitoring (TDM) arm with infliximab dosing optimised to target higher trough levels (TLI ≥ 25 μg/mL at week 2, ≥ 20 μg/mL at week 6, and ≥ 10 μg/mL during maintenance therapy)
Trial: 34210720
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing arm with conventional infliximab dosing (5 mg/kg at weeks 0, 2, and 6, and 5 mg/kg 8 weekly thereafter)
Trial: 32004214
Drug: Raltitrexed (Ra)
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed (Ra) with oxaliplatin (L‐OHP)
Trial: 33998949
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 50% effectiveness
Trial: 33998949
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 95% effectiveness
Trial: 35985196
Drug: Oligonol® supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oligonol® supplementation (200 mg per day)
Trial: 34624157
Drug: Machined surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machined surface (MS) implant sites
Trial: 34624157
Drug: Laser-microtextured surface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-microtextured surface (LMS) implant sites
Trial: 32168217
Drug: Low-dose copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose copper (175 mm) intrauterine contraceptive with a flexible nitinol frame
Trial: 35796019
Drug: NO2 reduction
RxNorm normalized name: REDUCTIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO2 reduction treatment (sham particle filtration and real NO2 scrubbing)
Trial: 35796019
Drug: Particle filtration
RxNorm normalized name: SNAIL SECRETION FILTRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Particle filtration treatment (HEPA filter and sham NO2 scrubbing)
Trial: 35796019
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (sham particle filtration and sham NO2 scrubbing)
Trial: 32500753
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin in combination with bendamustine and rituximab (BR)
Trial: 32500753
Drug: Polatuzumab vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Polatuzumab vedotin in combination with R-CHOP
Trial: 33331637
Drug: Dydrogesterone 40
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 40 mg orally, followed by 10 mg orally three times a day until 12 completed weeks of gestation or 1 week after bleeding stopped
Trial: 33808079
Drug: Spirulina supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina supplementation (6 g per day)
Trial: 36054253
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg daily plus montelukast 10 mg daily
Trial: 36054253
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg daily plus placebo
Trial: 34126052
Drug: On-site access
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site access to oral PrEP
Trial: 34126052
Drug: No on-site
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No on-site access to oral PrEP (before access)
Trial: 34126052
Drug: On-site access
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-site access to oral PrEP (within 180 days after access)
Trial: 34126052
Drug: No on-site
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No on-site access to oral PrEP (within 180 days before access)
Trial: 33715937
Drug: Crestal level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal level (CL) implants
Trial: 33715937
Drug: Supracrestal level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supracrestal level (SL) implants
Trial: 33023487
Drug: rTMS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rTMS treatment for upper limb recovery
Trial: 36385713
Drug: Topical melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical melatonin (25 mg/g) applied twice daily during radiation therapy
Trial: 36385713
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied twice daily during radiation therapy
Trial: 33402034
Drug: Sequential-with-tracing presentation
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential-with-tracing presentation of instructional arrows
Trial: 33402034
Drug: Sequential-without-tracing presentation
RxNorm normalized name: Trace metal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential-without-tracing presentation of instructional arrows
Trial: 33402034
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of arrows (both types)
Trial: 33718317
Drug: Reactive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive treatment intervention targeting household members of clinical malaria cases
Trial: 32075590
Drug: Prism Adaptation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prism Adaptation (PA) treatment
Trial: 33951328
Drug: A VitD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A VitD group (800 mg calcium and 0.5 μg active vitamin D)
Trial: 33951328
Drug: P-A VitD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-A VitD group (800 mg calcium, 0.5 μg active vitamin D, and physical exercise)
Trial: 33951328
Drug: P-NA VitD
RxNorm normalized name: Sodium phosphate P 32
DrugBank: Sodium phosphate P 32 (DB09370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P-NA VitD group (800 mg calcium, 800 IU non-active vitamin D, and physical exercise)
Trial: 32146471
Drug: Rechallenge with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rechallenge with previous treatment lines
Trial: 32980725
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T1C and T2
Trial: 35126568
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of Zintoma (ginger rhizome) capsules
Trial: 35126568
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg Zintoma capsules
Trial: 35126568
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg placebo capsules (containing chickpea flour)
Trial: 35126568
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg placebo capsules
Trial: 34621271
Drug: B cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell depleting therapy (anti-CD20 treatment)
Trial: 34621271
Drug: B cell
RxNorm normalized name: B cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B cell depleting therapy (rituximab vs ofatumumab)
Trial: 33788482
Drug: Tropisetron hydrochloride
RxNorm normalized name: tropisetron hydrochloride
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron hydrochloride intravenous (Control)
Trial: 35483400
Drug: Imiquimod treatment
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod treatment (self-administered, escalating dosage up to 3 times per week for 4-6 months)
Trial: 35813289
Drug: Sevoflurane inhalation
RxNorm normalized name: Sevoflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalation with manual infusion of remifentanil
Trial: 35813289
Drug: Effect-site target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effect-site target-controlled infusion of propofol and remifentanil
Trial: 33621601
Drug: Progesterone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone (100 mg subcutaneously twice daily for up to 5 days)
Trial: 32145678
Drug: Clemastine 1
RxNorm normalized name: clemastine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clemastine 1 mg orally twice a day for 90 days
Trial: 35921997
Drug: Standard implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard implant
Trial: 32527365
Drug: Partner non-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partner non-treatment
Trial: 32822347
Drug: Artesunate (AS)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AS) 2 mg/kg oral dose
Trial: 32651338
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg Dalfampridine extended release (D-ER)
Trial: 32651338
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Dalfampridine extended release (D-ER)
Trial: 35850588
Drug: Expressive art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressive art therapy (EAT) plus usual care (UC)
Trial: 32055629
Drug: Inhaled 0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled 0.9% normal saline by ultrasonic nebuliser with warming (UNW)
Trial: 32055629
Drug: Oral expectorant
RxNorm normalized name: pine tar/wild cherry ORAL EXPECTORANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral expectorant treatment
Trial: 33279662
Drug: RT and
RxNorm normalized name: Comfort and Ease KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT and BCAA (9 g/day)
Trial: 32437857
Drug: Two-step impression
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two-step impression in custom trays with border molding (impression compound) followed by polyether impression
Trial: 32993773
Drug: Warfarin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin plus nadroparin
Trial: 34765229
Drug: High-volume injection
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume injection with corticosteroid
Trial: 34765229
Drug: High-volume injection
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume injection without corticosteroid
Trial: 35605593
Drug: Standard stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard stroke treatment protocol including acupuncture
Trial: 35326326
Drug: Chlorogenic acids
RxNorm normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorogenic acids (CGA) 270 mg
Trial: 35640081
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral health education (control group)
Trial: 34750670
Drug: Intra wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra wound vancomycin (1-2 g)
Trial: 34538239
Drug: Daily clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily clinical warning signs (CWS) assessment
Trial: 34538239
Drug: Daily risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily risk scores using 7 CWS and MUAC<10.5cm
Trial: 32760749
Drug: Beating the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beating the Blues US (BtB) - 8-session internet cognitive-behavioral therapy for depression
Trial: 33085516
Drug: Purified lycopene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified lycopene (LYC) supplementation at 20 mg/kg diet for 12 weeks
Trial: 33201059
Drug: Topical fluorometholone
RxNorm normalized name: Fluorometholone
DrugBank: Fluorometholone (DB00324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical fluorometholone (FML)
Trial: 33201059
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A (CSA) 0.5% eye drops
Trial: 33293079
Drug: Concomitant radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant radiotherapy with chemotherapy (cRT)
Trial: 33293079
Drug: Radiotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy without concomitant chemotherapy (RT)
Trial: 36177347
Drug: Tenofovir Disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir Disoproxil (TD) 245 mg